Sigilon Therapeutics, Inc. (SGTX)
Sigilon Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $22.47, down 2.56% on the session, giving a market capitalisation of $56.2M. On trailing twelve-month figures it carries a trailing P/E of -16.77, a net margin of -335.7%. Its beta of 4.11 implies it has historically moved more than the broad market.
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
Sigilon Therapeutics, Inc. is most often compared with the following Healthcare names: